Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Real-World data unlock better skin disease care?

NCT ID NCT07748169

Knowledge-focused Sponsor: Target PharmaSolutions, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes, and medical events in routine clinical practice across the US, researchers hope to answer important questions about the effectiveness and safety of current treatments. The study also seeks to identify best practices and areas for improvement in dermatologic care, potentially informing future management strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This research could help identify which dermatology treatments work best in real-world settings and highlight gaps in care, potentially guiding better management strategies for conditions like vitiligo, eczema, and alopecia areata.
What could go wrong
As an observational study, it cannot prove cause and effect. The findings may be influenced by differences in patient populations or practice patterns, and the large scale may make detailed analysis challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

2,000,000

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants. * Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface. Exclusion Criteria: * Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia areata atopic eczema hidradenitis suppurativa skin disorder vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata Atopic dermatitis Hidradenitis suppurativa (HS) Vitiligo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Greenwich Village Dermatology

    New York, New York, 10012, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.